Corient Private Wealth LLC Buys 195,044 Shares of Illumina, Inc. (NASDAQ:ILMN)

Corient Private Wealth LLC raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 302.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 259,553 shares of the life sciences company’s stock after acquiring an additional 195,044 shares during the period. Corient Private Wealth LLC’s holdings in Illumina were worth $34,684,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ILMN. WCM Investment Management LLC lifted its stake in shares of Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after acquiring an additional 867,673 shares during the period. ARK Investment Management LLC acquired a new stake in shares of Illumina during the fourth quarter worth $91,714,000. Massachusetts Financial Services Co. MA raised its stake in Illumina by 148.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock worth $137,735,000 after buying an additional 631,294 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after buying an additional 625,245 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in Illumina by 116.9% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 865,546 shares of the life sciences company’s stock valued at $115,663,000 after acquiring an additional 466,519 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

NASDAQ ILMN opened at $85.68 on Tuesday. The company has a fifty day moving average price of $112.46 and a 200-day moving average price of $129.53. The firm has a market cap of $13.57 billion, a price-to-earnings ratio of -11.16, a PEG ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a 1 year low of $80.18 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities research analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Morgan Stanley lowered their price objective on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 11th. TD Cowen lowered Illumina from a “buy” rating to a “hold” rating and dropped their price target for the company from $177.00 to $140.00 in a research note on Friday, February 7th. HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective for the company. in a research report on Friday, February 28th. Robert W. Baird dropped their target price on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. Finally, Canaccord Genuity Group cut their target price on shares of Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.